Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

A legfontosabb adatok

Ki végzi
Yonsei University
Hol
Dél-Korea7 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
44 fő, tervezett
Kezdés
2021. júl. 5.
Várható befejezés
2027. máj. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Niraparib-Bevacizumab
A regiszteradat frissítve
2026. november 18.

Ki vehet részt

Életkor
20 év felett
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (34)A regiszter feltételeinek elrejtése

Egyéb feltételek

  • ## Inclusion Criteria
  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Participant has a histologically confirmed diagnosis of high-grade predominantly serous, endometrioid, carcinosarcoma, mixed Müllerian carcinoma with a high-grade serous component, clear cell, or low-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Only up to 4 participants with clear cell carcinoma will be included. Mucinous carcinoma will not be included
  • Participant has received at least 2 previous courses of platinum-containing therapy and has disease considered platinum-sensitive following the penultimate (next-to-last) platinum regimen, defined as more than 12 months between the penultimate platinum regimen and disease progression; Note: The last platinum regimen does not necessarily have to immediately follow the penultimate platinum regimen. Participants who received a non-platinum regimen between the penultimate and last platinum regimens may be eligible if all other entry criteria are met
  • Participant has achieved a complete response (CR) or partial response (PR) to the last platinum regimen, remains in response, and is enrolled within 8 weeks after completion of the last platinum regimen
  • Participant has received prior treatment with a PARP inhibitor
  • Participant is able to provide a newly obtained core or excisional biopsy of a tumor lesion for prospective testing of BRCA1/2 and PD-L1 status prior to enrollment
  • Female participant aged ≥20 years on the day of signing informed consent
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, assessed within 10 days prior to enrollment
  • Participant is not pregnant or breastfeeding and meets at least one of the following conditions:; Is not a woman of childbearing potential (WOCBP), as defined in Appendix 2; OR; Is a WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during treatment and for at least 180 days after the last dose of niraparib and at least 180 days after the last dose of chemotherapy or bevacizumab
  • Participant or a legally acceptable representative provides written informed consent. Consent for future biomedical research is optional and is not required for participation in the main study
  • Participant has adequate organ function according to the following laboratory criteria. All screening laboratory tests must be performed within 10 days prior to the start of study treatment; **Hematological Function:**
  • Absolute neutrophil count (ANC) ≥1,500/µL
  • Platelet count ≥100,000/µL
  • Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L, without erythropoietin dependency. **Renal Function:**
  • Serum creatinine ≤1.5 × upper limit of normal (ULN); OR
  • Measured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with serum creatinine >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. CrCl should be calculated according to institutional standards; **Hepatic Function:**
  • Total bilirubin ≤1.5 × ULN; OR direct bilirubin ≤ULN for participants with total bilirubin >1.5 × ULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases); **Coagulation Function:**
  • International normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range for the intended anticoagulant use; Note: Laboratory requirements should be adapted according to applicable local regulations and guidelines for the administration of specific chemotherapies; ## Exclusion Criteria; Participants are excluded from the study if any of the following criteria apply:
  • Participant has mucinous, germ cell, or borderline tumor of the ovary
  • Participant has a history of non-infectious pneumonitis requiring steroid treatment or currently has pneumonitis
  • Participant has myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or features suggestive of MDS/AML
  • Participant has an additional malignancy that is progressing or has required active treatment within the past 2 years; Exceptions:; Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical carcinoma in situ, or endometrial carcinoma) that has undergone potentially curative therapy; Synchronous primary endometrial cancer or a history of primary endometrial cancer not exceeding Stage IA, with no more than superficial myometrial invasion
  • Participant has undergone drainage of ascites during the last 2 cycles of the most recent chemotherapy
  • Participant has received palliative radiotherapy encompassing >20% of the bone marrow within 1 week
  • Participant has persistent toxicity greater than Grade 2 from prior cancer therapy
  • Participant has symptomatic uncontrolled brain or leptomeningeal metastases. A scan confirming the absence of brain metastases is not required. Participants with spinal cord compression may be eligible if they have received definitive treatment and have had clinically stable disease for 28 days
  • Participant has known hypersensitivity to the components of niraparib or bevacizumab
  • Participant has undergone major surgery within 3 weeks prior to starting study treatment or has not recovered from the effects of major surgery
  • Participant is considered a poor medical risk due to a serious uncontrolled medical disorder, non-malignant systemic disease, or active uncontrolled infection, including but not limited to:; Uncontrolled ventricular arrhythmia, myocardial infarction within the past 3 months, or congestive cardiac failure; Uncontrolled hypertension, defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, documented by 2 readings at least 1 hour apart; Arterial or venous thromboembolism; Uncontrolled cerebrovascular disease or predisposition to bleeding; Clinically significant intestinal obstruction, abdominal fistula, or gastrointestinal perforation; Uncontrolled major seizure disorder; Unstable spinal cord compression; Superior vena cava syndrome; Any psychiatric disorder that prevents obtaining informed consent
  • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that may confound study results, interfere with participation throughout study treatment, or make participation not in the participant's best interest
  • Participant is immunocompromised
  • Participant has known active hepatic disease, including hepatitis B or C

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is phase II, open label, clinical trial to determine the efficacy of Niraparib re-treatment with Bevacizumab of assessment progression-free survival(6 months PFS rate) with platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor.

A vizsgálat csoportja

  • experimentalA vizsgált kezelés

    Platinum-sensitive recurrent ovarian cancer patients previously treated with a PARP inhibitor, Non-mucinous

    Kezelés: Niraparib-Bevacizumab

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single-arm Phase II Study of Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Publikációk
A regiszteradat frissítve
2026. november 18.